# Stephen L. Chan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephen-l-chan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,984 |
| Field | Hepatocellular Carcinoma Treatment and Prognosis |
| h-index | 84 |
| i10-index | 257 |
| Last Known Institution | Chinese University of Hong Kong |
| OpenAlex ID | https://openalex.org/A5046498356 |
| ORCID iD | https://orcid.org/0000-0001-8998-5480 |
| Works | 721 |

## Researcher papers

- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-in-combination-with-gemcitabine-and-cisplatin-compared-with/)
- [Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments](https://scholariq.org/papers/plasma-dna-tissue-mapping-by-genome-wide-methylation-sequencing-for-noninvasive/)
- [Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma](https://scholariq.org/papers/four-year-overall-survival-update-from-the-phase-iii-himalaya-study-of/)
- [Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients](https://scholariq.org/papers/role-of-the-galad-and-balad-2-serologic-models-in-diagnosis-of-hepatocellular/)
- [Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/durvalumab-with-or-without-bevacizumab-with-transarterial-chemoembolisation-in/)

## Researcher topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)

## Researcher university

- [Chinese University of Hong Kong](https://scholariq.org/institutions/chinese-university-of-hong-kong/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.